AstraZeneca Q2 Sales Beat Estimates On Strong Cancer Drugs Revenues, Reaffirms 2025 Outlook

AstraZeneca Plc (NASDAQ:AZN) on Tuesday reported second-quarter 2025 sales of $14.46 billion, up 12% year over year (+11% at constant currency), marginally beating the consensus of $14.07 billion, driven by double-digit growth in oncology and biopharmaceuticals.

The company's adjusted EPADS reached $1.08, missing the consensus of $1.10. The adjusted EPS was $2.17 (1 ADR = 2 Common Shares).

Also Read: Trump Tariffs Force AstraZeneca To Bring Substantial Pharmaceutical Production To US

AstraZeneca's top business, oncology (cancer), accounted for 44% of total sales. It increased 18% (up 18% on constant currency) to $6.31 billion.

Tagrisso sales were up 13% to $1.81 billion (12% at CER), Imfinzi revenues were up 27% (+26%) to $1.46 billion, Calquence sales increased 10% to $872 million, Lynparza sales increased 13% (+11%) to $838 million, and Enhertu revenue was up 41% (42% at CER) to $666 million.

On Monday, the Food and Drug Administration (FDA)